(Reuters) – Eli Lilly (NYSE:) expects to start out promoting its weight-loss drug in Hong Kong as early as the tip of this 12 months, Bloomberg Information reported on Sunday.
The corporate has obtained the Hong Kong authorities approval to promote its tirzepatide injections — branded as Mounjaro — in a tool referred to as Kwikpen for each long-term weight administration and sort 2 diabetes, Eli Lilly instructed Bloomberg in a press release.